Clinical evidence shows that AposHealth (an FDA-cleared medical device) improves pain, stiffness, and function in people with knee osteoarthritis.
However, it’s uncertain if these improvements are clinically meaningful. The analyses suggest that AposHealth is cost saving by £1,958 per person when compared with standard care if knee surgery is delayed for 5 years. Because the evidence for the potential cost savings is limited, further data collection is recommended to understand if cost savings are made once AposHealth is used in the NHS.
Recent Posts
Overview of the Health Innovation Award 2026: Promoting Sustainable Solutions in Healthcare
The Health Innovation Award continues its mission in 2026 by spotlighting data-driven projects that advance sustainability across Portugal’s health sector. Launched by Faculdade de Medicina da Universidade de Lisboa, Sanofi, and NTT DATA Portugal, it invites submissions through its dedicated plat...
Commitment to Health Strategies in Portugal: A Pathway Towards Sustainable Change
In advancing health strategies in Portugal, the Ordem dos Farmacêuticos met with Adalberto Campos Fernandes to urge the country to move from promising ideas to concrete implementation of the
European Health Resilience: Strengthening Preparedness Amidst Geopolitical Challenges
EFPIA and Vaccines Europe endorse the European Commission’s Communication titled “Reinforcing Global Health Resilience Amidst Geopolitical Change,” published on 13 May, as a constructive advancement in bolstering European Health Resilience within a fragmented global environment. The statement hig...